CD274 and non-small cell lung carcinoma: Since PD-L1/PD1 signaling is necessary for maintaining TAMs as immunosuppressive macrophages in PD-L1-expressing cancers such as melanoma, non-small cell lung cancer, colorectal cancer and Hodgkin’s lymphoma [4,11,12], anti-PD1 antibodies (Abs) such as nivolumab and pembrolizumab could activate and re-polarize TAMs into anti-tumor macrophages.